Prognosis of patients with metastatic hepatocellular carcinoma (HCC).
H. Ishii,J. Furuse,M. Nagase,M. Yoshino,S. Takahashi,T. Nakagohri,M. Konishi,T. Kinoshita
DOI: https://doi.org/10.1200/jco.2004.22.14_suppl.4127
IF: 45.3
Journal of Clinical Oncology
Abstract:4127 Background: There has been no study regarding the long-term survival of a large number of metastatic HCC patients. The current study was conducted to clarify their prognostic factor.
METHODS
We surveyed 196 consecutive patients with metastatic HCC admitted to our hospital. We divided patients into subgroups according to their backgrounds, and compared survival times to determine favorable prognostic factors. We also analyzed relationship between the cause of death and site of metastasis.
RESULTS
The top 4 sites of the first metastasis were the lung in 78 patients, the bone in 69, an abdominal lymph node in 42, and the adrenal gland in 22. The first additional treatment after metastasis was observation in 58, surgery in 35, systemic chemotherapy in 14, transcatheter arterial chemoembolization in 41, and radiotherapy in 48. The median survival time and 1-, 3-, and 5-year survival rates were 4.5 months, and 31.1%, 9.7%, and 3.8%, respectively. Good performance status, good hepatic reserve, low alpha-fetoprotein, no bone metastasis, and low T factor were shown to be favorable significantly in survival time. Although 84% of the patients died of hepatic cause, patients with lung and bone metastasis tended to die due to lung metastasis and cachexia, respectively.
CONCLUSION
The prognosis of metastatic HCC patients was generally poor, however, there were long survivors among them. Their prognosis corresponded well to intrahepatic factors, i.e., primary cancer status and hepatic reserve. No significant financial relationships to disclose.